Revenue and Expenses - AgeX recognized revenues of $9,000 and $19,000 for the three and six months ended June 30, 2023, respectively, compared to $12,000 and $17,000 for the same periods in 2022, indicating a revenue decrease of approximately 25% for the three-month period [166]. - Cost of sales for the three and six months ended June 30, 2023, were $5,000 and $6,000, respectively, down from $6,000 and $7,000 in the same periods of 2022, reflecting a decrease of 16.67% for the three-month period [167]. - Research and development expenses decreased by approximately $0.1 million to $0.16 million for the three months ended June 30, 2023, a 38.2% decrease compared to $0.26 million in 2022 [169]. - General and administrative expenses increased by $0.4 million to $1.7 million for the three months ended June 30, 2023, a 29.3% increase compared to $1.3 million in 2022 [171]. - Total other expense, net for the three months ended June 30, 2023, was $1 million, primarily due to amortization of deferred debt issuance costs [175]. Financial Position and Cash Flow - AgeX incurred an accumulated deficit of $122.2 million as of June 30, 2023, and expects to continue incurring operating losses and negative cash flows [181]. - Net cash used in operating activities for the six months ended June 30, 2023, was $3.9 million, with a net loss attributable to the company of $6 million [190]. - Cash flows from investing activities included a $10 million loan made to Serina during the six months ended June 30, 2023 [191]. - Financing activities provided net cash of $13.5 million, entirely from credit facilities drawn from Juvenescence during the same period [192]. - The difference between net loss and cash used in operating activities was primarily due to non-cash items totaling $2.1 million [190]. - The company may need to modify or suspend operations if financing is unavailable or inadequate [188]. Strategic Initiatives - AgeX is pursuing a potential merger with Serina, which has not yet been finalized or approved by either company's board of directors [160][161]. - The company plans a potential spinoff of its subsidiary Reverse Bio, which would become a separate publicly traded company if completed [160]. - The company has made adjustments to its operating plans to reduce projected cash expenditures, including downsizing its leased office space and workforce [182]. - Operating expenses were reduced by outsourcing research and development, but this has hindered progress in developing target product candidates and technologies [186]. Operational Challenges - The company faced uncertainty regarding the impact of the COVID-19 pandemic on financing availability and overall operations [187]. - The ongoing pandemic's impact on business results remains highly uncertain and difficult to predict [187]. - There were no changes in internal control over financial reporting that materially affected the company's controls [194]. - The company is not currently involved in any material litigation or proceedings [196].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of exchange on which registered Common Stock, par value $0.0001 per share AGE NYSE American FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal execut ...

Financial Performance - Total revenues for the three months ended June 30, 2022, were $12,000, a decrease of 67.6% compared to $37,000 for the same period in 2021[22]. - Net loss attributable to AgeX for the six months ended June 30, 2022, was $5,324,000, compared to a net loss of $4,562,000 for the same period in 2021, representing an increase of 16.7%[22]. - The company reported a gross profit of $6,000 for the three months ended June 30, 2022, compared to $24,000 for the same period in 2021, a decline of 75%[22]. - AgeX recognized a gain of $106,000 from the deconsolidation of LifeMap Sciences, which is reported as a taxable transaction resulting in a taxable loss[92]. - The accumulated deficit as of June 30, 2022 was $111.1 million, indicating ongoing operating losses and negative cash flows since inception[185]. Cash and Liquidity - Cash and cash equivalents increased to $702,000 as of June 30, 2022, from $584,000 as of December 31, 2021, reflecting a growth of 20.2%[20]. - AgeX's cash and cash equivalents were $0.7 million as of June 30, 2022, which, along with a potential additional loan of $3.0 million, may not be sufficient to meet its funding requirements for the next twelve months[38]. - AgeX's total cash, cash equivalents, and restricted cash amounted to $752,000 as of June 30, 2022, compared to $634,000 as of December 31, 2021[56]. - Net cash used in operating activities from continuing operations for the six months ended June 30, 2022, was $3,382,000, compared to $4,234,000 for the same period in 2021, a decrease of 20.1%[28]. - The company expects to continue incurring operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern[186]. Expenses - Research and development expenses for the three months ended June 30, 2022, were $259,000, a decrease of 46.1% from $481,000 for the same period in 2021[22]. - General and administrative expenses for the six months ended June 30, 2022, were $2,998,000, down 20.5% from $3,770,000 for the same period in 2021[22]. - AgeX incurred approximately $11,000 and $57,000 of allowable expenses under the NIH grant for the three and six months ended June 30, 2021, respectively[68]. - Total other expense, net for the six months ended June 30, 2022 was $1.7 million, consisting of $1.4 million amortization of deferred debt issuance costs and $0.3 million unrealized loss on warrants[179]. - For the six months ended June 30, 2022, stock-based compensation expense totaled $437,000, compared to $464,000 for the same period in 2021[141]. Debt and Financing - AgeX had drawn the full $8.0 million line of credit under the 2020 Loan Agreement, with the outstanding principal balance due on March 30, 2023[98]. - AgeX has drawn $10,160,000 from a $13,160,000 line of credit under the Secured Convertible Promissory Note, with an outstanding principal balance due on February 14, 2024[101]. - The company may sell up to $12.1 million of additional shares of common stock in "at-the-market" transactions to raise capital[188]. - AgeX's total debt balances net of issuance costs amounted to $18.63 million, with debt issuance costs totaling $7.92 million[120]. - The company faces challenges in obtaining necessary capital due to ongoing net operating losses and debt obligations to Juvenescence[203]. Stock and Equity - The weighted average number of common shares outstanding for the three months ended June 30, 2022, was 37,943,000, compared to 37,936,000 for the same period in 2021[22]. - As of June 30, 2022, AgeX had 37,945,108 shares of common stock issued and outstanding, an increase from 37,941,220 shares at December 31, 2021[132]. - AgeX issued warrants to purchase 6,502,442 shares of common stock in connection with $10,160,000 of drawdowns from Juvenescence under the Secured Note during the six months ended June 30, 2022[133]. - AgeX's stockholders' equity was reported to be less than $2,000,000, leading to a deficiency letter from the NYSE American regarding continued listing standards[156]. - AgeX regained compliance with the NYSE American's continued listing standards on April 15, 2021, but remains subject to normal continued listing monitoring[157]. Operational Changes - The company has initiated staff reductions and eliminated laboratory facilities to reduce operating expenses amid the COVID-19 pandemic[39]. - The company has deferred in-house development of its product candidates and technologies due to staffing reductions and the closing of research laboratory facilities[203]. - AgeX's operations and financial results may be impacted by the ongoing COVID-19 pandemic, with uncertainty regarding the duration and scope of its effects[167]. - The ongoing COVID-19 pandemic may adversely impact the availability of financing and disrupt operations, adding to the uncertainty of future capital needs[190]. - The company is exploring options for obtaining additional capital, including the sale of common stock and collaborative research arrangements[203]. Research and Development - AgeX plans to finance its iTR research and development through its subsidiary Reverse Bioengineering, Inc.[46]. - AgeX's research and development expenses consist primarily of personnel costs, stock-based compensation, and outside consultants[72]. - Research and development expenses for the six months ended June 30, 2022 were $0.7 million, reflecting a focus on outsourcing rather than internal development[192]. - The company has a Sponsored Research Agreement with the University of California at Irvine for the derivation of neural stem cells, with initial work expected to conclude during 2022[166]. - AgeX does not expect to earn subscription and advertising revenues in subsequent accounting periods due to the LifeMap Deconsolidation[65].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or ot ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-1436829 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-38519 AgeX Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...